\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesA newly published Commission communication outlines the EU's commitment to boost Biotechnology and Biomanufacturing in the EU for a sustainable & competitive future and emphasizes their vital role to address global challenges. The document summarises the current challenges and barriers for biotechnology and biomanufacturing and proposes actions to address these challenges in a timely manner. The paper makes the case for a more coordinated approach for biotechnology and biomanufacturing policies and explores ways to foster engagement and collaboration, including through international cooperation.
The document touches upon the importance of the Biotech and Biomanufacturing Initiative in Healthcare, Food Security, Sustainable Forestry and Global Marine Challenges and stresses the aligment with the goals of the European Green Deal and European Health Union. It sets out measures in the regulatory, industrial, economic and social dimensions, including significant investment in infrastructure and know-how and ensuring that it can reap the benefits of the EU single market.
For more details, read the Commission press release and the full communication.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
